Literature DB >> 22443956

"Switching adalimumab from syringe to pen. Expected outcomes".

Hèctor Corominas, Silvia Garcia-Diaz, Lucinda Sanchez-Eslava, Ramon Fíguls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22443956     DOI： 10.1517/14712598.2012.676033

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


× No keyword cloud information.
  2 in total

1.  Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Authors:  Roy M Fleischmann; Amy E Bock; Wuyan Zhang; Charles M Godfrey; Ivana Vranic; Carol Cronenberger; Eva Dokoupilová
Journal:  Rheumatol Ther       Date:  2022-03-18

2.  Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.

Authors:  Raphael J Dehoratius; Lawrence H Brent; Jeffrey R Curtis; Lorie A Ellis; Kezhen L Tang
Journal:  Patient       Date:  2018-06       Impact factor: 3.883
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.